Nonsteroidal anti-inflammatory drug effectivity in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis

Juan Pablo Román Serrano; José Jukemura; Samuel Galante Romanini; Paúl Fernando Guamán Aguilar; Juliana Silveira Lima de Castro; Isabela Trindade Torres; José Andres Sanchez Pulla; Otavio Micelli Neto; Eloy Taglieri; José Celso Ardengh

doi:10.4253/wjge.v12.i11.469

Nonsteroidal anti-inflammatory drug effectivity in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis

World J Gastrointest Endosc. 2020 Nov 16;12(11):469-487. doi: 10.4253/wjge.v12.i11.469.

Affiliations

¹ Department of Gastroenterology, University of Sao Paulo, São Paulo 05403-000, São Paulo, Brazil. hcjprs2412@hotmail.com.
² Department of Gastroenterology, University of Sao Paulo, São Paulo 05403-000, São Paulo, Brazil.
³ Department of Gastrointestinal Endoscopy Service, Hospital 9 de Julho, São Paulo 01409002, São Paulo, Brazil.
⁴ Department of Gastroinestinal, Catholic University of Cuenca, Cuenca 010101, Ecuador.
⁵ Department of General Surgery, Servidor Municipal Hospital, São Paulo 01532-001, Brazil.

Abstract

Background: Endoscopic retrograde cholangiopancreatography (ERCP) is the primary therapeutic procedure for the treatment of diseases affecting the biliary tree and pancreatic duct. Although the therapeutic success rate of ERCP is high, the procedure can cause complications, such as acute pancreatitis [post-ERCP pancreatitis (PEP)], bleeding and perforation.

Aim: To assess the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in preventing PEP during follow-up.

Methods: Databases such as MEDLINE, EMBASE and Cochrane Central Library were searched. Only randomized controlled trials (RCTs) comparing the efficacy of NSAIDs and placebo for the prevention of PEP were included. Outcomes evaluated included the incidence of PEP, severity of pancreatitis, route of administration, types, dose, and timing of administration of NSAIDs.

Results: Twenty-six RCTs were considered eligible with a total of 8143 patients analyzed. Overall, 4020 patients used NSAIDs before ERCP and 4123 did not use NSAIDs (control group). Ultimately, 298 cases of post-ERCP acute pancreatitis were diagnosed in the NSAID group and 484 cases in the placebo group. The risk of PEP was lower in the NSAID group risk difference (RD): -0.04; 95% confidence interval (CI): -0.07 to - 0.03; number needed to treat (NNT), 25; P < 0.05. NSAID use effectively prevented mild pancreatitis compared to placebo use (2.5% vs 4.1%; 95%CI: -0.05 to -0.01; NNT, 33; P < 0.05), but information on moderate PEP and severe PEP could not be fully elucidated. Only rectal administration reduced the incidence of PEP with RD: -0.06; 95%CI: -0.08 to -0.04; NNT, 17; P < 0.05). Furthermore, only the use of diclofenac or indomethacin was effective in preventing PEP, at a dose of 100 mg, which must be administered before performing ERCP.

Conclusion: Rectal administration of diclofenac and indomethacin significantly reduced the risk of developing mild PEP. Additional RCTs are needed to compare the efficacy between NSAID routes of administration in preventing PEP.

Keywords: Diclofenac; Endoscopic retrograde cholangiopancreatography; Indomethacin; Pancreatitis; Rectal.